Navigation Links
NEUMANN Diagnostics' Automated Cervical Cancer Test Achieves Exceptional Accuracy
Date:2/3/2016

BUDAPEST, Hungary, Feb. 3, 2016 /PRNewswire/ -- Molecular assays developer NEUMANN Diagnostics Ltd. today unveiled its CONFIDENCE™ molecular test portfolio setting a new standard in cervical cancer screening.

The tests demonstrated superior accuracy achieving very high sensitivity without compromising on specificity. In HPV-positive women aged 25 years or older sensitivity for severe cervical dysplasia or worse condition at baseline was 91.94% (95% CI 82.17 – 97.33) meanwhile specificity in the same group was 74.35% (95% CI 71.78 – 76.81).

The CONFIDENCE™ test portfolio (consisting of a human papillomavirus test (HPV) and an epigenetic biomarker) was evaluated in a multicentre clinical trial involving over 7,000 cervical samples collected from over 6,000 women. This clinical trial makes the CONFIDENCE™ biomarker the most validated epigenetic biomarker for cervical cancer diagnostics.

"We are very pleased with the results of the study. This is the first highly accurate screening method in the world with fully automated evaluation," said Miklós Nyíri, managing director of NEUMANN.

Initially NEUMANN intends to introduce the test to complement current screening methods. Its biomarker test can help substantially increase the sensitivity of Pap testing without impacting specificity. 

"What is needed the most today is increasing sensitivity of the current screening system and finding women in need of treatment as early as possible" – said Nyíri. "We recommend using the CONFIDENCE™ tests on all samples which did not get a severe dysplasia diagnosis – because there is a potentially undetected underlying disease."

In the clinical trial the CONFIDENCE™ tests found severe cases up to 12 months earlier than Pap smear.

When no sign of malignancy is found with conventional methods, NEUMANN's test, with a proprietary algorithm, can establish the individual risk of each woman for cervical pre-cancer or cancer.  

One of the first clients of NEUMANN for its HPV diagnostics technology is the Synlab GenoID Molecular Laboratory, part of the Synlab Group, Europe's largest laboratory network.

The aim of NEUMANN is to prove its method can be a standalone solution for cervical cancer screening in any environment – including in developing countries where cytopathology is non-existent.

About NEUMANN

NEUMANN develops automated diagnostic testing systems for cancer screening and STDs. The company is majority owned by the X-Ventures Beta Venture Capital Fund co-financed by Hungarian private investors and the EIB in the Joint European Resources for Micro to Medium Enterprises (Jeremie) program.

www.neumanndx.com

Contact:

Ms Anna Faludi
email: anna.faludi@x-ventures.hu
tel: +36-70-454-3254

 

Photo - http://photos.prnewswire.com/prnh/20160128/326991   
Logo - http://photos.prnewswire.com/prnh/20160128/326990LOGO

 


'/>"/>
SOURCE NEUMANN
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Der automatisierte Gebärmutterhalskrebs-Test von NEUMANN Diagnostics erreicht eine außergewöhnliche Genauigkeit
2. MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013
3. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
4. Apnix Sleep Diagnostics Announces New Houston Sleep Apnea Treatments
5. MGC Diagnostics Corporation Reports 2013 Second Quarter Operating Results
6. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
7. Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders
8. In Vitro Diagnostics - A Global Market Overview
9. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
10. Quest Diagnostics CEO Steve Rusckowski Reaffirms Full-Year 2013 Guidance At The Jefferies 2013 Global Healthcare Conference
11. Quest Diagnostics and Hologic Form Strategic Alliance to Improve Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):